- AgeX Therapeutics, Inc. is a longevity-focused biotechnology company aiming to develop novel therapeutics for human aging and degenerative diseases.
- AgeX's current pipeline consists of three primarily cell-based pre-clinical programs focused on using vascular endothelial progenitor cells and brown adipocytes to treat diabetes, obesity, and heart disease.
- AgeX is in a poor financial position with less than 12 months of cash, even after incorporating the minimal $1.6M in 2020 revenues, expected to be much lower after LifeMap's 2021 cash-out-merger.
- AgeX and LyGenesis, Inc announced in March 2021 their intention to proceed with negotiations on a merger of the two companies. LyGenesis is a privately held clinical-stage biotech developing complementary cell therapies for organ regeneration.
- In summary, the author projects AgeX Therapeutics, Inc. as a risky "hold".
For further details see:
AgeX Therapeutics: New LyGenesis Merger May Unlock Much-Needed Value